Literature DB >> 21909634

Effects of modafinil on cognitive functions in first episode psychosis.

Linda Scoriels1, Jennifer H Barnett, Praveen K Soma, Barbara J Sahakian, Peter B Jones.   

Abstract

RATIONALE: Cognitive impairments are important determinants of functional outcome in psychosis, which are inadequately treated by antipsychotic medication. Modafinil is a wake-promoting drug that has been shown to improve attention, memory and executive function in the healthy population and in patients with schizophrenia.
OBJECTIVES: We aimed to establish modafinil's role in the adjunctive treatment of cognitive impairments in the first episode of psychosis, a time when symptoms may be more malleable than at chronic stages of the disease.
METHODS: Forty patients with a first episode of psychosis participated in a randomised, double-blind, placebo-controlled crossover design study assessing the effects of a single dose of 200 mg modafinil on measures of executive functioning, memory, learning, impulsivity and attention.
RESULTS: Modafinil improved verbal working memory (d = 0.24, p = 0.04), spatial working memory errors (d = 0.30, p = 0.0004) and strategy use (d = 0.23, p = 0.03). It also reduced discrimination errors in a task testing impulsivity. Modafinil showed no effect on impulsivity measures, sustained attention, attentional set-shifting, learning or fluency.
CONCLUSIONS: Modafinil selectively enhances working memory in first episode psychosis patients, which could have downstream effects on patients' social and occupational functioning.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909634     DOI: 10.1007/s00213-011-2472-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  A UK strategy for mental health and wellbeing.

Authors:  Barbara J Sahakian; Gavin Malloch; Christopher Kennard
Journal:  Lancet       Date:  2010-05-29       Impact factor: 79.321

2.  Diagnostic stability over one year in first-episode psychosis.

Authors:  Jean Addington; Ana Chaves; Donald Addington
Journal:  Schizophr Res       Date:  2006-06-05       Impact factor: 4.939

3.  Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States.

Authors:  Alison R Yung; Hok Pan Yuen; Patrick D McGorry; Lisa J Phillips; Daniel Kelly; Margaret Dell'Olio; Shona M Francey; Elizabeth M Cosgrave; Eoin Killackey; Carrie Stanford; Katherine Godfrey; Joe Buckby
Journal:  Aust N Z J Psychiatry       Date:  2005 Nov-Dec       Impact factor: 5.744

4.  Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies.

Authors:  B Saletu; R Frey; M Krupka; P Anderer; J Grünberger; M J Barbanoj
Journal:  Arzneimittelforschung       Date:  1989-10

5.  The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type.

Authors:  B Sahakian; G Jones; R Levy; J Gray; D Warburton
Journal:  Br J Psychiatry       Date:  1989-06       Impact factor: 9.319

6.  Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI.

Authors:  Michael J Minzenberg; Andrew J Watrous; Jong H Yoon; Stefan Ursu; Cameron S Carter
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

Review 7.  Early detection and intervention of psychosis. A review.

Authors:  Raimo K R Salokangas; Thomas H McGlashan
Journal:  Nord J Psychiatry       Date:  2008       Impact factor: 2.202

Review 8.  Intervention in individuals at ultra-high risk for psychosis: a review and future directions.

Authors:  Patrick D McGorry; Barnaby Nelson; G Paul Amminger; Andreas Bechdolf; Shona M Francey; Gregor Berger; Anita Riecher-Rössler; Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Merete Nordentoft; Ian Hickie; Philip McGuire; Michael Berk; Eric Y H Chen; Matcheri S Keshavan; Alison R Yung
Journal:  J Clin Psychiatry       Date:  2009-06-30       Impact factor: 4.384

9.  Reflection impulsivity in current and former substance users.

Authors:  Luke Clark; Trevor W Robbins; Karen D Ersche; Barbara J Sahakian
Journal:  Biol Psychiatry       Date:  2006-01-31       Impact factor: 13.382

10.  Impaired conscious and preserved unconscious inhibitory processing in recent onset schizophrenia.

Authors:  V C Huddy; A R Aron; M Harrison; T R E Barnes; T W Robbins; E M Joyce
Journal:  Psychol Med       Date:  2008-09-16       Impact factor: 7.723

View more
  16 in total

Review 1.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

Review 2.  The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Authors:  M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2015-07-24       Impact factor: 4.530

Review 3.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

Review 4.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

5.  Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults.

Authors:  Hsun-Hua Chou; Jo A Talledo; Sarah N Lamb; Wesley K Thompson; Neal R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2013-01-12       Impact factor: 4.530

Review 6.  Modafinil for people with schizophrenia or related disorders.

Authors:  Javier Ortiz-Orendain; Sergio A Covarrubias-Castillo; Alan Omar Vazquez-Alvarez; Santiago Castiello-de Obeso; Gustavo E Arias Quiñones; Maya Seegers; Luis Enrique Colunga-Lozano
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12

7.  Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers.

Authors:  U Müller; J B Rowe; T Rittman; C Lewis; T W Robbins; B J Sahakian
Journal:  Neuropharmacology       Date:  2012-07-20       Impact factor: 5.250

8.  Behavioural and molecular endophenotypes in psychotic disorders reveal heritable abnormalities in glutamatergic neurotransmission.

Authors:  L Scoriels; R M Salek; E Goodby; D Grainger; A M Dean; J A West; J L Griffin; J Suckling; P J Nathan; B R Lennox; G K Murray; E T Bullmore; P B Jones
Journal:  Transl Psychiatry       Date:  2015-03-31       Impact factor: 6.222

Review 9.  The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people.

Authors:  Barbara J Sahakian; Annette B Bruhl; Jennifer Cook; Clare Killikelly; George Savulich; Thomas Piercy; Sepehr Hafizi; Jesus Perez; Emilio Fernandez-Egea; John Suckling; Peter B Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

10.  The effect of modafinil on the rat dopamine transporter and dopamine receptors D1-D3 paralleling cognitive enhancement in the radial arm maze.

Authors:  Yasemin Karabacak; Sunetra Sase; Yogesh D Aher; Ajinkya Sase; Sivaprakasam R Saroja; Ana Cicvaric; Harald Höger; Michael Berger; Vasiliy Bakulev; Harald H Sitte; Johann Leban; Francisco J Monje; Gert Lubec
Journal:  Front Behav Neurosci       Date:  2015-08-19       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.